Pluristem Therapeutics Profit Margin

Pluristem Therapeutics (PSTI) currently reports a profit margin of -870.11% as of March 2026. That compares with -3010.28% in the prior-year period — up 71.1% year over year. That is below the Healthcare sector average of 13.89%. Use the charts on this page to explore Pluristem Therapeutics's profit margin history and peer comparisons.

Pluristem Therapeutics's profit margin increased from -3010.28% to -870.11% — a 71.1% year-over-year increase (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Pluristem Therapeutics's profit margin of -870.11% is lower than the Healthcare sector average of 13.89%. That is roughly 6362.9% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Pluristem Therapeutics's current -870.11% should be judged against Healthcare norms (sector average: 13.89%) and against PSTI's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -870.11%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 13.89%. From there, open related valuation or income-statement pages for Pluristem Therapeutics, and consider following PSTI for alerts when major investors trade the stock.